Back to Search
Start Over
17α Hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
- Source :
-
Reproductive toxicology (Elmsford, N.Y.) [Reprod Toxicol] 2012 Jan; Vol. 33 (1), pp. 15-9. Date of Electronic Publication: 2011 Nov 20. - Publication Year :
- 2012
-
Abstract
- Use of 17-alpha-hydroxyprogesterone caproate for the prevention of spontaneous preterm birth in women at risk is reviewed. Early studies regarding this topic reached contradicting conclusions, however recent studies showed that weekly injections of 17-alpha-hydroxyprogesterone caproate beginning at 16-20 weeks' gestation resulted in a substantial reduction in the rate of spontaneous recurrent preterm birth. Long-term follow-up of children exposed in-utero to the drug has shown normal growth and development and normal scores for gender specific roles. In conclusion, 17-alpha-hydroxyprogesterone caproate is currently the only drug with sufficient evidence to support its use for prevention of spontaneous recurrent preterm birth.<br /> (Copyright © 2011 Elsevier Inc. All rights reserved.)
- Subjects :
- 17 alpha-Hydroxyprogesterone Caproate
Abnormalities, Drug-Induced etiology
Animals
Cost Savings
Cost-Benefit Analysis
Drug Administration Schedule
Drug Costs
Evidence-Based Medicine
Female
Gestational Age
Humans
Hydroxyprogesterones administration & dosage
Hydroxyprogesterones adverse effects
Hydroxyprogesterones economics
Hydroxyprogesterones pharmacokinetics
Injections
Pregnancy
Premature Birth economics
Premature Birth etiology
Recurrence
Risk Assessment
Risk Factors
Hydroxyprogesterones therapeutic use
Premature Birth prevention & control
Subjects
Details
- Language :
- English
- ISSN :
- 1873-1708
- Volume :
- 33
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Reproductive toxicology (Elmsford, N.Y.)
- Publication Type :
- Academic Journal
- Accession number :
- 22120850
- Full Text :
- https://doi.org/10.1016/j.reprotox.2011.10.017